Related Experiment Video
Updated: Jan 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Discovery of Novel 1,3,4-oxadiazole-based Inhibitors Against Urease and Diabetes: Design, Synthesis, SAR, Biological,
Sabeen Arshad1, Aneela Maalik1, Wajid Rehman2
1Department of Chemistry, COMSATS University Islamabad campus-45550, Islamabad, Pakistan.
Introduction:
Heterocyclic compounds bearing oxygen and nitrogen atoms are key pharmacophores in modern drug design. Among them, 1,3,4-oxadiazoles are notable for their diverse biological activities, including anti-inflammatory, anticancer, antidiabetic, antibacterial, and enzyme inhibitory effects. This study focuses on the synthesis and evaluation of indazole-based 1,3,4-oxadiazole-benzenesulfonothioate hybrids as potential therapeutic agents.
Methods:
A multistep synthetic route was employed to develop a series of eighteen (18) analogues. The synthetic strategy involved the formation of methyl 5-methyl-1H-indazole-3-carboxylate, conversion to carbohydrazide, cyclization with CS2, and final coupling with substituted benzenesulfonyl chlorides to yield the target hybrids (1-18).
Results:
The urease inhibition potential of scaffolds ranged from IC50 = 17.88 ± 0.36 to 37.98 ± 0.80 μM as compared to the standard drug thiourea (IC50 = 29.45 ± 0.76 μM). The exceptional urease and α-glucosidase activity was shown by scaffolds (4, 7, 9, 11) due to the presence of electron- withdrawing groups (-F, NO2, and Cl). In comparison, the α-glucosidase inhibition potential shown by all the scaffolds was in the range (IC50 = 3.19 ± 0.27 - 12.24 ± 1.33 μM). Compound-9 showed promising inhibitory potential against urease, with an IC50 = 17.90 ± 0.30 μM, and α- glucosidase (IC50 = 3.19 ± 0.27 μM), both indicating minimum IC50 values.
Discussion:
The enhanced activity of compounds bearing electron-withdrawing groups (F, NO2, Cl) supports their role in modulating enzyme inhibition. In silico molecular docking further confirmed strong binding affinities with the active sites of target enzymes, correlating well with the experimental results.
Conclusion:
The synthesized 1,3,4-oxadiazole derivatives demonstrate promising dual inhibitory activity against urease and α-glucosidase, suggesting their potential as lead compounds in the treatment of gastric infections and diabetes. This study contributes to the ongoing development of multifunctional therapeutic agents with improved efficacy and selectivity.
More Related Videos
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
Enzyme Inhibition
Oral Hypoglycemic Agents: Sulfonylureas
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Dipeptidyl Peptidase 4 Inhibitors

